Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Payers' Guide
Drug Updates
,
Payers' Guide
Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
Lisa A. Raedler, PhD, RPh
Read More
Drug Updates
,
Payers' Guide
Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide
Abraxane (nab-Paclitaxel) Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide
Adempas (Riociguat): A Novel, First-in-Class Therapy Approved for the Treatment of 2 Types of Pulmonary Hypertension
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide
Amitiza (Lubiprostone): The First Oral Treatment Approved by the FDA for Opioid-Induced Constipation
Loretta Fala
Read More
Payers' Guide
Anoro Ellipta (Umeclidinium/Vilanterol): First Dual Long-Acting Inhaler for Long-Term Maintenance Treatment of COPD
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide
Botox (OnabotulinumtoxinA) Now FDA Approved for Overactive Bladder
Loretta Fala
Read More
Payers' Guide
Breo Ellipta (Fluticasone Furoate/Vilanterol): Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD
Loretta Fala
Read More
Payers' Guide
Brintellix Tablets (Vortioxetine) Approved by the FDA for the Treatment of Major Depressive Disorder
Loretta Fala
Read More
Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2013
Read More
11
12
13
14
15
16
17
Page 14 of 19
Results 131 - 140 of 185